A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis.

IF 2.7 4区 医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-03 DOI:10.1080/1750743X.2024.2365619
Min Pan, Jianrong Xue
{"title":"A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis.","authors":"Min Pan, Jianrong Xue","doi":"10.1080/1750743X.2024.2365619","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To assess the effectiveness and safety of a new protocol for adjusting doses during interrupted subcutaneous immunotherapy maintenance, exceeding an 8-week interval, with mite allergen injections in children with allergic rhinitis.<b>Patients & methods:</b> 194 children with allergic rhinitis who underwent subcutaneous immunotherapy and experienced interruptions lasting more than 8 weeks during maintenance were enrolled. Following the adoption of a novel dose-adjustment protocol, a real-world study was conducted.<b>Results:</b> After 3 years of subcutaneous immunotherapy, the novel group exhibited a significant reduction in allergy symptoms compared with baseline. Systemic reactions related to the novel protocol did not significantly increase.<b>Conclusion:</b> The novel protocol was deemed safe and effective, offering advantages of time savings and reduced burdens.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"749-758"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2365619","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To assess the effectiveness and safety of a new protocol for adjusting doses during interrupted subcutaneous immunotherapy maintenance, exceeding an 8-week interval, with mite allergen injections in children with allergic rhinitis.Patients & methods: 194 children with allergic rhinitis who underwent subcutaneous immunotherapy and experienced interruptions lasting more than 8 weeks during maintenance were enrolled. Following the adoption of a novel dose-adjustment protocol, a real-world study was conducted.Results: After 3 years of subcutaneous immunotherapy, the novel group exhibited a significant reduction in allergy symptoms compared with baseline. Systemic reactions related to the novel protocol did not significantly increase.Conclusion: The novel protocol was deemed safe and effective, offering advantages of time savings and reduced burdens.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过敏性鼻炎患儿间断皮下免疫疗法的新剂量调整方案。
目的:评估过敏性鼻炎患儿在中断皮下免疫疗法维持治疗期间(间隔时间超过 8 周)注射螨虫过敏原调整剂量的新方案的有效性和安全性。患者和方法:194 名过敏性鼻炎患儿接受了皮下注射免疫疗法,在维持治疗期间中断了超过 8 周的时间。在采用新的剂量调整方案后,进行了一项真实世界研究。研究结果经过 3 年的皮下免疫疗法后,与基线相比,新方案组的过敏症状明显减轻。与新方案相关的全身反应没有明显增加。结论新方案被认为安全有效,具有节省时间和减轻负担的优点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature. Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China. ctDNA-guided adjuvant immunotherapy in colorectal cancer. Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance? Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1